SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-038016
Filing Date
2024-02-16
Accepted
2024-02-16 06:23:32
Documents
18
Period of Report
2024-02-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d721402d8k.htm   iXBRL 8-K 35809
2 EX-1.1 d721402dex11.htm EX-1.1 218481
3 EX-4.1 d721402dex41.htm EX-4.1 73951
4 EX-5.1 d721402dex51.htm EX-5.1 10521
8 GRAPHIC g721402dsp66.jpg GRAPHIC 3463
  Complete submission text file 0001193125-24-038016.txt   554809

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA prme-20240214.xsd EX-101.SCH 2869
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE prme-20240214_lab.xml EX-101.LAB 17979
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE prme-20240214_pre.xml EX-101.PRE 11271
19 EXTRACTED XBRL INSTANCE DOCUMENT d721402d8k_htm.xml XML 3625
Mailing Address 21 ERIE ST. CAMBRIDGE MA 02139
Business Address 21 ERIE ST. CAMBRIDGE MA 02139 617-465-0013
Prime Medicine, Inc. (Filer) CIK: 0001894562 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41536 | Film No.: 24645712
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)